Specific mRNA molecule may be useful as biomarker in ALS

Specific mRNA molecule may be useful as biomarker in ALS

A messenger RNA (mRNA) molecule that provides the instructions for a protein involved in glutamate signaling is not edited as efficiently in amyotrophic lateral sclerosis (ALS) patients as in people without the neurological disorder, according to a new study suggesting its potential use as an ALS biomarker. Glutamate is…

Pegcetacoplan fails to improve ALS outcomes in MERIDIAN trial

Apellis Pharmaceuticals’ investigational therapy pegcetacoplan (APL-2) has failed to improve a combined assessment of function and survival in people with amyotrophic lateral sclerosis (ALS), according to top-line data from the MERIDIAN Phase 2 clinical trial. While the treatment was well tolerated, consistent with its established safety profile,…

All MLB teams playing on Lou Gehrig Day June 2

Today marks the third annual Major League Baseball (MLB) Lou Gehrig Day, set aside to honor the legacy of the famed New York Yankees first baseman whose career was shortened by amyotrophic lateral sclerosis (ALS). For the first time since the event began, all 30 MLB teams have…

EMA committee leaning toward not recommending AMX0035 approval

A committee of the European Medicines Agency (EMA) is leaning toward not recommending a conditional approval of Amylyx Pharmaceuticals’ AMX0035 for treating amyotrophic lateral sclerosis (ALS) in the European Union. The drug is already marketed in the U.S. under the name Relyvrio (sodium phenylbutyrate and taurursodiol) and…

Gout medication decreases risk of ALS and other diseases: Study

Allopurinol and carvedilol, two medications respectively used to manage gout and high blood pressure, significantly reduce the chances of developing amyotrophic lateral sclerosis (ALS), Alzheimer’s, or Parkinson’s disease, a new study suggests. “These findings suggest a possible new direction for repurposing or developing medications for neuroprotection,” Brad…